相关临床试验
9
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1998
已完成
2
22.2%
尚未招募
1
11.1%
招募中
1
11.1%
Unknown
4
44.4%
撤回
1
11.1%
暂无批准数据
- Researchers reviewed 77 meta-analyses spanning 116 different bipolar disorder treatments to identify the most effective interventions across age groups and mood phases. - The team created EBI-BD, an open-access web platform presenting each treatment's impact, side effects, and strength of evidence to support shared decision-making. - For bipolar depression, effective adult treatments include cariprazine, fluoxetine, and lurasidone, while lurasidone and olanzapine with fluoxetine were effective in children and teenagers. - The review's results have already been used to update CANMAT and International Society for Bipolar Disorders (ISBD) treatment guidelines.
- The Ottawa Hospital's Biotherapeutics Manufacturing Centre (BMC) has rebranded as Boreal Biomanufacturing, signaling a commitment to becoming a national and global biomanufacturing centre of excellence. - Boreal has developed more than 20 distinct cell- and virus-based products for human clinical trials, including the first made-in-Canada CAR-T therapy and oncolytic cancer-fighting viruses. - In 2029, Boreal will move into the University of Ottawa's Advanced Medical Research Centre (AMRC), expanding its capacity to support more simultaneous viral vector and cell therapy manufacturing programs. - The expansion is funded by Canada's Biosciences Research Infrastructure Fund and the Ontario Research Fund, and Boreal remains owned and operated by The Ottawa Hospital.
- Ontario will lower the colorectal cancer screening eligibility age from 50 to 45 for average-risk individuals, effective July 1, 2026, opening screening access to over one million more Ontarians. - The policy also reduces the screening age for those at increased risk to 40, or 10 years before the youngest age a first-degree relative was diagnosed, whichever comes first. - The decision follows rising colorectal cancer incidence in adults under 50 and aligns with guidance from the Canadian Cancer Society and clinical experts. - Patient advocacy group CCRAN, which has campaigned for this change since 2020, now urges all remaining Canadian provinces and territories to adopt the same screening threshold.
- The COBRRA trial found that apixaban reduced bleeding risk by more than half compared to rivaroxaban in 2,760 patients with acute venous thromboembolism over three months. - Clinically relevant bleeding occurred in 3.3% of apixaban patients versus 7.1% of rivaroxaban patients, with no significant difference in blood clot recurrence rates. - Despite higher medication adherence with rivaroxaban (75.1% vs 65.7%), the safety advantage of apixaban remained consistent across the international study. - The findings provide the first head-to-head comparison of these commonly prescribed anticoagulants and may influence clinical practice guidelines for venous thrombosis treatment.
- The National Research Council of Canada has developed a novel CAR T-cell therapy targeting the CD22 protein on B-cell leukemia and lymphoma cells, offering hope for patients who failed previous CD19-targeted treatments. - Clinical trials for this made-in-Canada therapy are expected to begin in late 2023 across Vancouver, Ottawa, and Toronto, focusing on both pediatric and adult lymphoblastic leukemia and lymphoma patients. - The NRC's approach aims to establish domestic biomanufacturing facilities across Canada, potentially making CAR T-cell therapies more affordable and accessible compared to current imported options that come with high costs and long wait times.
